[go: up one dir, main page]

WO1994013672A1 - Neue triazolochinazoline, ihre herstellung und verwendung - Google Patents

Neue triazolochinazoline, ihre herstellung und verwendung Download PDF

Info

Publication number
WO1994013672A1
WO1994013672A1 PCT/EP1993/003331 EP9303331W WO9413672A1 WO 1994013672 A1 WO1994013672 A1 WO 1994013672A1 EP 9303331 W EP9303331 W EP 9303331W WO 9413672 A1 WO9413672 A1 WO 9413672A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
triazolo
quinazolin
group
triazoloquinazolines
Prior art date
Application number
PCT/EP1993/003331
Other languages
German (de)
English (en)
French (fr)
Inventor
Rainer Schlecker
Hans-Joerg Treiber
Berthold Behl
Hans Peter Hofmann
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Priority to PL93309339A priority Critical patent/PL309339A1/xx
Priority to EP94901897A priority patent/EP0673377B1/de
Priority to DE59305551T priority patent/DE59305551D1/de
Priority to AU56284/94A priority patent/AU674909B2/en
Priority to US08/446,844 priority patent/US5631261A/en
Priority to JP6513724A priority patent/JPH08504411A/ja
Priority to KR1019950702353A priority patent/KR950704317A/ko
Publication of WO1994013672A1 publication Critical patent/WO1994013672A1/de
Priority to FI952855A priority patent/FI952855L/fi
Priority to NO952292A priority patent/NO952292L/no
Priority to GR970400809T priority patent/GR3023147T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the present invention relates to new triazoloquinazolines, processes for their preparation and their use for combating diseases.
  • Pyrazolo- and triazoloquinazolines are already known which have anti-allergic and anti-inflammatory properties (EP 80,176, US 4,053,600, US 4,128,644). Pyrazolo-quinazolines are also known, which are also suitable for the treatment of thrombosis and neurological disorders (US 5,153,196).
  • A is a C 5 alkylene group
  • X is a carboxyl group, which may be in the form of its salt with a physiologically compatible amine or metal cation; -the rest
  • R 4 is a C ⁇ _s-alkyl radical, a cycloalkyl group with 3 to 8 carbon atoms in the ring, a benzyl radical, one of the radicals - (CH 2 ) n -0-R 5 or
  • n is the number 2, 3 or 4 and R 5 and R 6 represent a C ⁇ _ 3 alkyl group; represents a hydroxyl, C ⁇ -hydroxyalkyl, C ⁇ _ alkylcarbonyl, nitrile 0-C ⁇ _alkyl, tetrazolyl, carbonylaminotetrazole or an optionally substituted carbamoyl group, and R 1 and R 2 , which may be the same or different, Wasser ⁇ Substance, fluorine, chlorine or bromine atoms, trifluoromethyl, cyano, nitro, amino, C ⁇ _ 5 alkyl, mono- or di-C ⁇ _ 5 alkyl amino groups, a C ⁇ -6-alkylthio, C ⁇ - 6 -Alkylsulfenyl-, Ci-g-alkylsulfonyl, aminosulfonyl, Di-C ⁇ _ 6 -alkylaminosul- fonylrest mean or
  • R 1 and R 2 together represent a methylene or ethylenedioxy group or a straight-chain C 3 _ 5 alkylene group, or mean an aromatic or heterocyclic ring, show a different spectrum of activity.
  • R 1 is a hydrogen or chlorine atom or a trifluoromethyl, nitro or C 3 alkyl group and R 2 is a chlorine atom or a trifluoromethyl, nitro or C ⁇ _ 3 alkyl group or R 1 and R 2 together represent a straight-chain C 3 _ 5 alkylene group or an aromatic ring.
  • Cyanomethyl, 1-cyanoethyl, 1-cyanopropyl, 2-cyanopropyl, 3-cyano-propyl, 1-cyanobutyl, 2-cyanobutyl, 3-cyanobutyl, 4-cyanobutyl The following may be mentioned as basic bodies without the substituent AX:
  • the compounds of the formula I are prepared by an intramolecular condensation reaction of a hydrazinoquinazoline of the formula II,
  • R 4 is a Ci- ⁇ -alkyl radical, a cycloalkyl group having 3 to 8 carbon atoms in the ring, a benzyl ring or the radical - (CH 2 ) -OR 5 and Y represents a hydroxyl group or a bromine or chlorine atom, preferably in the presence of a dehydrating agent, in particular phosphorus oxychloride, polyphosphoric acid or acetic acid, optionally in an inert solvent such as toluene, chlorobenzene, xylene or excess acetic acid, at temperatures of 50 up to 150 ° C, preferably at the reflux temperature of the reaction mixture.
  • a dehydrating agent in particular phosphorus oxychloride, polyphosphoric acid or acetic acid
  • an inert solvent such as toluene, chlorobenzene, xylene or excess acetic acid
  • esters thus obtained can then be saponified and the free acids can be converted into physiologically compatible salts with an amine or a metal cation.
  • esters of the formula I can also be subjected to a conventional transesterification process corresponding to the meanings for the R 4 radical.
  • alkali metals such as sodium and potassium
  • alkaline earth metals such as calcium
  • other metals such as aluminum
  • salts of organic bases such as morpholine, piperidine, mono-, di- and triethanolamine or tris (hydroxymethyl) aminomethane, which are generally known to the person skilled in the art.
  • Carboxylic acids of the formula I can also be prepared by hydrogenolysis of the corresponding benzyl esters by known methods, as described, for example, in Houben-Weyl, vol. IV / lc, p. 381 ff.
  • the reaction takes place in the presence of a catalyst, such as platinum, palladium or nickel, advantageously on a support, in particular carbon, in a solvent, such as a lower alcohol, in particular methanol, acetic acid or a dialkylformamide, in particular dimethylformamide, between temperatures from 0 ° C. to to the boiling point of the solvent, and preferably under only slightly elevated pressure.
  • a catalyst such as platinum, palladium or nickel
  • a ide of formula I, in which X represents a carbamoyl group by reacting the ester with ammonia or amines in the presence of a solvent such as water, a lower alcohol, an aqueous-alcoholic solution or dialkylformamide at temperatures between 0 ° C. and the reflux temperature of the system.
  • a solvent such as water, a lower alcohol, an aqueous-alcoholic solution or dialkylformamide at temperatures between 0 ° C. and the reflux temperature of the system.
  • a dehydrating agent such as phosphorus pentoxide, phosphorus oxychloride or thionyl chloride
  • X represents a nitrile group.
  • the reaction is generally carried out with an excess of the dehydrating agent at the reflux temperature of the mixture.
  • the reaction can optionally be carried out in the presence of an inert solvent, such as benzene or ethylene chloride.
  • reaction is usually carried out in an inert solvent, such as, for example, methylene chloride, dioxane, tetrahydrofuran or dimethylformamide, preferably in the presence of a condensation reagent known from peptide chemistry, such as N, N'-carbonyldiimidazole or N, N'-dicyclohexylcarbodiimide, at Tem ⁇ temperatures from 20 ° C to 120 ° C carried out.
  • condensation reagent known from peptide chemistry, such as N, N'-carbonyldiimidazole or N, N'-dicyclohexylcarbodiimide
  • substituents R 1 and R 2 are not yet present in the starting compounds, these can also be introduced subsequently. This can be done by an electrophilic aromatic substitution of a compound of the formula I obtained, in which R 1 and / or R 2 are hydrogen atoms, according to methods known per se, as described, for example, in Houben-Weyl Vol. X / l, p. 471 ff , Vol. IX, p. 572 ff, and vol. V / 3, p. 873.
  • nitration can be carried out with a mixture of sulfuric and nitric acid at room temperature, sulfonation, for example with chlorosulfonic acid between room temperature and 150 ° C., chlorination with sulfuryl chloride at 20 ° C. to 100 ° C.
  • the starting compounds of the formula II are prepared in a manner known per se by condensation of a hydrazinoquinazoline of the formula IV
  • R 1 , R 2 and Y have the meanings given above, with a dicarboxylic acid ester halide or a dicarboxylic acid diester.
  • an ester halide preferably a chloride
  • the reaction is advantageously carried out at temperatures from -30 ° C. to 70 ° C., preferably at room temperature, in an inert solvent such as dimethylformamide, dioxane, tetrahydrofuran or methylene chloride.
  • the reaction is preferably carried out in the presence of tertiary organic bases, such as triethylamine or pyridine.
  • reaction of IV with esters can be carried out with or without a solvent, such as toluene, chlorobenzene or diphenyl ether, at a temperature from about 20 ° C. to the reflux temperature of the mixture.
  • a solvent such as toluene, chlorobenzene or diphenyl ether
  • R 1 , R 2 and Y have the meaning given above and X is a nucleofugic leaving group, preferably a halogen atom, such as, for example, chlorine.
  • X is a nucleofugic leaving group, preferably a halogen atom, such as, for example, chlorine.
  • the reaction is carried out between 0 ° C and 50 ° C in an inert solvent such as ethanol, methylene chloride, toluene, tetrahydrofuran or dimethylformamide, preferably with an excess of V.
  • the compounds I according to the invention are suitable as active pharmaceutical ingredients for human and veterinary medicine and can be used for the production of medicaments for the treatment of neurodegenerative diseases and neutoxic disorders of the central nervous system and for the production of spasmolytics, antiepileptics, anxiolytics and antidepressants.
  • the pharmacological activity of the compounds I according to the invention was investigated on isolated membrane material from rat cerebrum.
  • the membrane material in the presence of the compounds according to the invention with the radioactively labeled substances 3 H-2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid ( 3 H-AMPA) and 3 H-2-amino-3- treated with hydroxy-5-methyl-4-isoxazole-propionic acid ( 3 H-AMPA) and 3 H-5,7-dichlorokynurenic acid, these being directed to specific receptors (AMPA or NMDA receptor (N-methyl-D- bind aspartate)).
  • AMPA or NMDA receptor N-methyl-D- bind aspartate
  • rat cerebrums were added together with the approx. 15-fold volume of a buffer solution A consisting of 30 ⁇ ffi ⁇ o, ⁇ -tris (hydroxymethyl) methyl a in hydrochloride (TRIS-HC1) and 0.5 mM ethylenediaminetetra - acetic acid (EDTA) - pH 7.4 - homogenized using an Ultra-TURRAX stirrer.
  • the suspension was centrifuged at 48,000 g for 20 min. After the supernatant liquid had been separated off, the proteinaceous membrane material contained in the sediment was washed three times by suspending it in buffer solution A and then centrifuging at 48,000 g for 20 minutes each. The membrane material was then suspended in a 15-fold volume of buffer solution A and incubated at 37 ° C. for 30 minutes. The protein material was then washed twice by centrifugation and suspension and frozen at -70 ° C until used.
  • the protein material thawed at 37 ° C. was centrifuged twice at 48,000 g (20 minutes) and then suspended in a buffer solution B consisting of 50 mM TRIS-HC1, 0.1 M potassium thiocyanate and 2.5 mM Calcium chloride - pH 7.1 - washed. Then 0.25 mg of membrane material, 0.1 ⁇ Ci 3 H-AMPA (60 Ci / mol) and compound I were dissolved in 1 ml of buffer solution B and incubated on ice for 60 minutes. The incubated solution was over a
  • CF / B filter (Whathman), which had previously been treated with a 0.5% aqueous solution of polyethyleneimine for at least 2 hours, was filtered. The filtrate was then washed with 5 ml of cold buffer solution B in order to separate bound and free 3 H-AMPA from one another. After measuring the radioactivity of the bound 3 H-AMPA in the membrane material Scintillation counting was determined by evaluating the displacement curves by means of regression analysis of the Kj value
  • rat cerebrums were homogenized together with the approximately 10-fold volume of a buffer solution A 'of 50 mM TRIS-HC1 and 10 mM EDTA - pH 7.4.
  • the suspension was centrifuged at 48,000 g for 20 minutes. After the supernatant liquid had been separated off, the membrane material contained in the sediment was washed twice by suspending it in the buffer solution A 'and then centrifuging and suspending for 20 minutes each. After resuspending the membrane in the buffer solution A 'and freezing in liquid nitrogen, the suspension was thawed again at 37 ° C. and, after a further washing process, incubated at 37 ° C. for 15 minutes.
  • the protein material was then washed four times by centrifugation and suspension and frozen at -70 ° C. until used.
  • the protein material thawed at 37 ° C. was washed twice by centrifugation at 48,000 g (20 minutes) and subsequent suspension in a buffer solution B ′ from 50 mM TRIS-HC1 - pH 7.4. 0.15 mg of membrane material, 0.3 ⁇ Ci 3 H-5,7-dichlorokynurenic acid (16 Ci / mmol) and compound I were then dissolved in 1 ml of buffer solution B 'and incubated on ice for 30 minutes. The incubated solution was centrifuged at 150,000 g for 2 minutes. After the supernatant had been separated off, the sediments were suspended twice with 1.5 ml of cold buffer solution B '. After measurement of the radioactivity of the 3 H-5,7-dichlorokynurenic acid bound to the membranes in the sediment, the result was K - [- value by evaluating the displacement curves using the regression analysis.
  • the pharmaceutical preparations are prepared in the usual way, e.g. by mixing the active ingredient with the other conventional carriers and diluents.
  • the pharmaceutical preparations can be administered in various ways of administration, such as orally, parenterally, subcutaneously, intraperitonally and topically.
  • forms of preparation such as tablets, emulsions, infusion and injection solutions, pastes, ointments, gels, creams, lotions, powders and sprays are possible.
  • the pharmaceutical preparations according to the invention contain a therapeutically effective amount of compound I.
  • the active ingredients can be contained in the usual concentrations.
  • the active substances are contained in an amount of 0.001 to 5% by weight, preferably 0.02 to 0.5% by weight.
  • the preparations are administered in single doses. 0.1 to 50 mg, preferably 0.1 to 10 mg, of active ingredient are administered in a single dose per kg of body weight.
  • the preparations can be administered daily in one or more doses depending on the type and severity of the diseases.
  • the daily dose is generally 0.1 to 100 mg per kg body weight with oral administration or 0.01 to 10 mg per kg body weight with parenteral administration.
  • the pharmaceutical preparations according to the invention contain the usual carriers and diluents in addition to the active ingredient.
  • auxiliaries such as ethanol, isopropanol, ethoxylated castor oil, ethoxylated hydrogenated castor oil, polyacrylic acid, polyethylene glycol, polyethylene glycol stearate, ethoxylated fatty alcohols, paraffin oil, petroleum jelly and wool fat can be used.
  • Milk sugar, propylene glycol, ethanol, starch, talc and polyvinylpyrrolidone are suitable for internal use.
  • Antioxidants such as tocopherol and butylated hydroxyanisole and butylated hydroxytoluene, taste-improving additives, stabilizers, emulsifiers and bleaches can also be present.
  • the substances contained in the preparation in addition to the active substance and the substances used in the manufacture of the pharmaceutical preparation must be toxicologically safe and compatible with the respective active substance.
  • Example 2 3.5 g of the substance of Example 2 were stirred in 70 ml of 1 N sodium hydroxide solution at room temperature overnight. The solution was extracted with CH 2 Cl 2 , the water phase was adjusted to pH 1 with 1 N hydrochloric acid and the precipitate was filtered off with suction, washed with water and dried. Yield: 2.8 g (84%); Mp 266-270 ° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/EP1993/003331 1992-12-10 1993-11-27 Neue triazolochinazoline, ihre herstellung und verwendung WO1994013672A1 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL93309339A PL309339A1 (en) 1992-12-10 1993-11-27 Novel triazoquinazolines, methods of obtaining them and their application
EP94901897A EP0673377B1 (de) 1992-12-10 1993-11-27 Neue triazolochinazoline, ihre herstellung und verwendung
DE59305551T DE59305551D1 (de) 1992-12-10 1993-11-27 Neue triazolochinazoline, ihre herstellung und verwendung
AU56284/94A AU674909B2 (en) 1992-12-10 1993-11-27 New triazoloquinazolines, their production and their use
US08/446,844 US5631261A (en) 1992-12-10 1993-11-27 Triazoloquinazolines, their preparation and use
JP6513724A JPH08504411A (ja) 1992-12-10 1993-11-27 新規トリアゾロキナゾリン、その製造および使用
KR1019950702353A KR950704317A (ko) 1992-12-10 1993-11-27 신규 트리아졸로퀴나졸린, 그의 제조 방법 및 그의 용도(New Triazoloquinazolines, Their Production and Their Use)
FI952855A FI952855L (fi) 1992-12-10 1995-06-09 Uudet triatsolokinatsoliinit, niiden valmistus ja käyttö
NO952292A NO952292L (no) 1992-12-10 1995-06-09 Nye triazolokinazoliner, deres fremstilling og anvendelse
GR970400809T GR3023147T3 (en) 1992-12-10 1997-04-15 New triazoloquinazolines, their production and their use.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4241563A DE4241563A1 (de) 1992-12-10 1992-12-10 Neue Triazolochinazoline, ihre Herstellung und Verwendung
DEP4241563.2 1992-12-10

Publications (1)

Publication Number Publication Date
WO1994013672A1 true WO1994013672A1 (de) 1994-06-23

Family

ID=6474849

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/003331 WO1994013672A1 (de) 1992-12-10 1993-11-27 Neue triazolochinazoline, ihre herstellung und verwendung

Country Status (23)

Country Link
US (1) US5631261A (xx)
EP (1) EP0673377B1 (xx)
JP (1) JPH08504411A (xx)
KR (1) KR950704317A (xx)
CN (1) CN1095380A (xx)
AT (1) ATE149167T1 (xx)
AU (1) AU674909B2 (xx)
CA (1) CA2151242A1 (xx)
CZ (1) CZ145095A3 (xx)
DE (2) DE4241563A1 (xx)
DK (1) DK0673377T3 (xx)
ES (1) ES2098119T3 (xx)
FI (1) FI952855L (xx)
GR (1) GR3023147T3 (xx)
HU (1) HUT72301A (xx)
IL (1) IL107917A (xx)
MX (1) MX9307736A (xx)
NO (1) NO952292L (xx)
NZ (1) NZ258557A (xx)
PL (1) PL309339A1 (xx)
TW (1) TW345580B (xx)
WO (1) WO1994013672A1 (xx)
ZA (1) ZA939227B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103224498A (zh) * 2013-05-07 2013-07-31 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128644A (en) * 1977-07-29 1978-12-05 E. R. Squibb & Sons, Inc. Pyrazolo(1,5-c)quinazoline derivatives and related compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053600A (en) * 1973-03-08 1977-10-11 Sandoz, Inc. Tricyclic 1,2,4-triazolo-quinazolines
DE3146599A1 (de) * 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128644A (en) * 1977-07-29 1978-12-05 E. R. Squibb & Sons, Inc. Pyrazolo(1,5-c)quinazoline derivatives and related compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.E. FRANCIS ET AL.: "Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6h)-0nes", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, 1991, WASHINGTON US, pages 281 - 290 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103224498A (zh) * 2013-05-07 2013-07-31 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法
CN103224498B (zh) * 2013-05-07 2015-10-28 陈定奔 两种唑并喹唑啉酮稠杂环的新合成方法

Also Published As

Publication number Publication date
DE4241563A1 (de) 1994-06-16
AU5628494A (en) 1994-07-04
PL309339A1 (en) 1995-10-02
DE59305551D1 (de) 1997-04-03
GR3023147T3 (en) 1997-07-30
EP0673377A1 (de) 1995-09-27
US5631261A (en) 1997-05-20
NO952292D0 (no) 1995-06-09
NZ258557A (en) 1997-06-24
KR950704317A (ko) 1995-11-17
FI952855A0 (fi) 1995-06-09
MX9307736A (es) 1994-06-30
AU674909B2 (en) 1997-01-16
CZ145095A3 (en) 1995-12-13
EP0673377B1 (de) 1997-02-26
CA2151242A1 (en) 1994-06-23
CN1095380A (zh) 1994-11-23
NO952292L (no) 1995-06-09
TW345580B (en) 1998-11-21
HUT72301A (en) 1996-04-29
JPH08504411A (ja) 1996-05-14
HU9501691D0 (en) 1995-08-28
ZA939227B (en) 1995-06-09
ATE149167T1 (de) 1997-03-15
IL107917A (en) 1997-03-18
IL107917A0 (en) 1994-04-12
DK0673377T3 (da) 1997-03-17
ES2098119T3 (es) 1997-04-16
FI952855L (fi) 1995-06-09

Similar Documents

Publication Publication Date Title
DE1695556C3 (de) 3-Alkyl-1,2,3,4,4a,9-hexahydropyrazino[1,2-f]morphanthridinderivate
EP0148440B1 (de) 1,3,4,5-Tetrahydrobenz[c,d]indole, ein Verfahren zu ihrer Herstellung und ihre Verwendung
DE4217952A1 (de) Chinoxalin-2,3(1H,4H)-dione
DE4242675A1 (de) Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung
EP0691970B1 (de) Imidazolochinoxalinonderivate als eaa antagonisten
WO1997049701A1 (de) Pyrrolylchinoxalindione, ihre herstellung und verwendung als ampa-rezeptorantagonisten
EP0799224B1 (de) Chinoxaline und arzneimittel daraus
EP0673377B1 (de) Neue triazolochinazoline, ihre herstellung und verwendung
WO1996010572A1 (de) Neue heterocyclische substituierte imidazolo-chinoxalinone, ihre herstellung und verwendung
EP0785932B1 (de) Pyrrolyl-tetrahydrobenzochinoxalindione, ihre herstellung und verwendung als glutamatrezeptor-antagonisten
JPS6322562A (ja) 強心性、ホスホジエステラ−ゼ画分１１１抑制性及び／又は腎血管拡張性を持った４−窒素置換イソキノリノ−ル化合物
EP0003558A1 (de) 9-(3-Piperidinopropyl)-purin-Derivate, Verfahren zu deren Herstellung, deren Verwendung sowie diese Verbindungen enthaltende Arzneimittel
DE4428152A1 (de) Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
EP0673378B1 (de) Neue triazolopyrimidone, ihre herstellung und verwendung
DE4329970A1 (de) Neue Imidazolo-chinoxalinone, ihre Hestellung und Verwendung
EP0160173A1 (de) Benzothiazolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltendes Arzneimittel
EP0113911B1 (de) Pyrido-triazolochinazoline, ihre Herstellung und Verwendung
DE2521519A1 (de) Substituierte 9,10-dihydroanthracen- 9,10-imine und heterocyclische (aza) analoge davon und verfahren zur herstellung dieser verbindungen
WO1994025472A1 (de) Pyrido[1,2,3-de]chinoxalinderivate, verfahren zu deren herstellung und ihre verwendung in arzneimitteln
DE2215999A1 (de) Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung
DE1695381A1 (de) Phthalazino(2,3-b)phthalazin-5(14H),12(7H)-dione und Verfahren zu ihrer Herstellung
WO1997008168A1 (de) Pyrrolyl-tetrahydrochinoxalindione, ihre herstellung und verwendung zur bekämpfung von krankheiten
DE3907389A1 (de) Neue 1,7-anellierte 1h-indol-carbonsaeure-n-(5-alkyl-1,4-benzodiazepin-3-yl)amide
DE3329505A1 (de) Neue tetrazinderivate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994901897

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 258557

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 08446844

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PV1995-1450

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2151242

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 952855

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1994901897

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1995-1450

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1995-1450

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1994901897

Country of ref document: EP